Proportion of participants with endophthalmitis · people with neovascular age‐related macular degeneration
Extended‐fixed showed no clear difference in endophthalmitis (ocular adverse event) compared with monthly injections (low certainty).
1 finding from 1 review
Change in BCVA at 1 year (ETDRS letters score, the higher the score the better) · people with neovascular age‐related macular degeneration
1 finding from 1 review
Gain of 3 or more lines of visual acuity · people with neovascular age‐related macular degeneration
Extended‐fixed showed no clear difference in gain of ≥ 15 letters visual acuity at 1 year compared with monthly injections (moderate certainty).
1 finding from 1 review
Overall survival
Extended‐field radiotherapy probably leads to lower overall survival compared with pelvic radiotherapy (moderate certainty).
1 finding from 1 review
Para‐aortic lymph node recurrence
Extended‐field radiotherapy probably leads to lower para‐aortic lymph node recurrence compared with pelvic radiotherapy (moderate certainty).
1 finding from 1 review
Progression‐free survival
Extended‐field radiotherapy showed no clear difference in progression‐free survival compared with pelvic radiotherapy (moderate certainty).
1 finding from 1 review
Adverse events
Extended‐field radiotherapy showed no clear difference in adverse events compared with pelvic radiotherapy (moderate certainty).
1 finding from 1 review
Overall survival
Extended‐field radiotherapy probably leads to lower overall survival compared with pelvic chemoradiotherapy (moderate certainty).
1 finding from 1 review
Para‐aortic lymph node recurrence
Extended‐field radiotherapy may leads to lower para‐aortic lymph node recurrence compared with pelvic chemoradiotherapy (low certainty).
1 finding from 1 review
Progression‐free survival
Extended‐field radiotherapy probably leads to lower progression‐free survival compared with pelvic chemoradiotherapy (moderate certainty).
1 finding from 1 review
Acute adverse events
Extended‐field radiotherapy probably leads to lower acute adverse events compared with pelvic chemoradiotherapy (moderate certainty).
1 finding from 1 review
Late adverse events
Extended‐field radiotherapy showed no clear difference in late adverse events compared with pelvic chemoradiotherapy (moderate certainty).
1 finding from 1 review
HIV transmission at 6 months among those whose HIV diagnostic testing was negative within 96 hours of birth · HIV‐infected mothers and their breastfeeding infants
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in HIV transmission at 6 months among those whose HIV diagnostic… compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
1 finding from 1 review
Infant Mortality at 6 Months · HIV‐infected mothers and their breastfeeding infants
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in infant Mortality at 6 months compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
1 finding from 1 review
HIV Transmission or Death at 6 months among those whose HIV diagnostic testing was negative within 96 hours of birth · HIV‐infected mothers and their breastfeeding infants
It is very uncertain whether an extended ZDV/3TC/LPV/r regimen administered to mothers changes HIV Transmission or Death at 6 months among those whose HIV… compared with an extended ZDV/3TC/ABC administered to mothers (very low certainty).
1 finding from 1 review
Infant Grade 3/4 Severe Adverse Events · HIV‐infected mothers and their breastfeeding infants
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in infants with Grade 3/4 Severe Adverse Events compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
1 finding from 1 review
Maternal mortality ‐ not reported · HIV‐infected mothers and their breastfeeding infants
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in maternal Mortality at 6 months compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
1 finding from 1 review
Maternal Grade 3/4 Severe Adverse Events · HIV‐infected mothers and their breastfeeding infants
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in mothers with any Grade 3/4 Severe Adverse Event compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
1 finding from 1 review
Mothers with Severe Adverse Events Requiring Treatment Modification · HIV‐infected mothers and their breastfeeding infants
It is very uncertain whether an extended ZDV/3TC/LPV/r regimen administered to mothers changes mothers with Severe Adverse Events Requiring Treatment Modification compared with an extended ZDV/3TC/ABC administered to mothers (very low certainty).
1 finding from 1 review
Days missed from work or school · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review